Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612001004853
Ethics application status
Approved
Date submitted
17/09/2012
Date registered
18/09/2012
Date last updated
9/07/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of common sleeping pills on arousal and muscle function during sleep
Scientific title
Effects of common sedatives on respiratory arousal and upper airway muscle function during sleep in healthy men and women with and without sleep apnoea
Secondary ID [1] 281240 0
Nil
Universal Trial Number (UTN)
Nil
Trial acronym
Nil
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Sleep apnoea 287432 0
Condition category
Condition code
Respiratory 287767 287767 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Arm 1: temazepam (10mg), once only immediately before going to bed, taken orally
Arm 2 zopiclone (7.5mg), once only immediately before going to bed, taken orally
Arm 3: zolpidem (10mg), once only immediately before going to bed, taken orally
1 week washout between treatments
Intervention code [1] 285707 0
Treatment: Drugs
Comparator / control treatment
Placebo, taken orally (participants will act as thier own controls in a cross-over design)
Control group
Placebo

Outcomes
Primary outcome [1] 287996 0
Respiratory arousal threshold (negative pharyngeal pressure immediately prior to arousal from sleep using an epiglottic pressure catheter inserted via the nostril)
Timepoint [1] 287996 0
Acute overnight studies on drug vs. placebo
Secondary outcome [1] 299227 0
Upper airway muscle responsiveness (EMG)
Timepoint [1] 299227 0
Acute overnight studies on drug vs. placebo
Secondary outcome [2] 299228 0
Upper airway collapsibility (Pcrit)
Timepoint [2] 299228 0
Acute overnight studies on drug vs. placebo
Secondary outcome [3] 299229 0
Respiratory control stability (loop gain)
Timepoint [3] 299229 0
Acute overnight studies on drug vs. placebo
Secondary outcome [4] 299230 0
Ventilatory responses
Timepoint [4] 299230 0
Acute overnight studies on drug vs. placebo

Eligibility
Key inclusion criteria
Healthy men and women with and without sleep apnoea
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
-Known allergy or previous adverse reaction to temazepam, zopiclone or zolpidem
-Medications known to affect muscle activity or sleep
-Pregnant or nursing mothers

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
25/09/2012
Actual
27/09/2012
Date of last participant enrolment
Anticipated
Actual
26/08/2015
Date of last data collection
Anticipated
Actual
8/10/2015
Sample size
Target
25
Accrual to date
Final
28
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 286018 0
University
Name [1] 286018 0
University of New South Wales
Country [1] 286018 0
Australia
Funding source category [2] 287829 0
Government body
Name [2] 287829 0
NHMRC (APP1042493)
Country [2] 287829 0
Australia
Primary sponsor type
Other
Name
Neuroscience Research Australia
Address
Barker Street
Randwick
NSW 2031
Country
Australia
Secondary sponsor category [1] 284834 0
None
Name [1] 284834 0
Address [1] 284834 0
Country [1] 284834 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288069 0
University of New South Wales Human Research Ethics Committee
Ethics committee address [1] 288069 0
Ethics committee country [1] 288069 0
Australia
Date submitted for ethics approval [1] 288069 0
Approval date [1] 288069 0
14/03/2012
Ethics approval number [1] 288069 0
HC12028

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34718 0
Dr Danny Eckert
Address 34718 0
Neuroscience Research Australia Barker Street Randwick, NSW 2031
Country 34718 0
Australia
Phone 34718 0
+61 2 9399 1814
Fax 34718 0
Email 34718 0
d.eckert@neura.edu.au
Contact person for public queries
Name 17965 0
Dr. Danny Eckert
Address 17965 0
Neuroscience Research Australia
Barker Street
Randwick, NSW
2031
Country 17965 0
Australia
Phone 17965 0
+61 2 9399 1814
Fax 17965 0
Email 17965 0
d.eckert@neura.edu.au
Contact person for scientific queries
Name 8893 0
Dr. Danny Eckert
Address 8893 0
Neuroscience Research Australia
Barker Street
Randwick, NSW
2031
Country 8893 0
Australia
Phone 8893 0
+61 2 9399 1814
Fax 8893 0
Email 8893 0
d.eckert@neura.edu.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.